ID   NRX1A_RAT               Reviewed;        1530 AA.
AC   Q63372;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-OCT-2024, entry version 190.
DE   RecName: Full=Neurexin-1;
DE   AltName: Full=Neurexin I-alpha;
DE   AltName: Full=Neurexin-1-alpha;
DE   Flags: Precursor;
GN   Name=Nrxn1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 13A), INTERACTION WITH
RP   ALPHA-LATROTOXIN, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Brain;
RX   PubMed=1621094; DOI=10.1126/science.1621094;
RA   Ushkaryov Y.A., Petrenko A.G., Geppert M., Suedhof T.C.;
RT   "Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin
RT   receptor and laminin.";
RL   Science 257:50-56(1992).
RN   [2]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=7695896; DOI=10.1016/0896-6273(95)90306-2;
RA   Ullrich B., Ushkaryov Y.A., Suedhof T.C.;
RT   "Cartography of neurexins: more than 1000 isoforms generated by alternative
RT   splicing and expressed in distinct subsets of neurons.";
RL   Neuron 14:497-507(1995).
RN   [3]
RP   PROTEIN SEQUENCE OF N-TERMINUS, AND INTERACTION WITH NXPH1 AND NXPH3.
RX   PubMed=9856994; DOI=10.1074/jbc.273.52.34716;
RA   Missler M., Hammer R.E., Suedhof T.C.;
RT   "Neurexophilin binding to alpha-neurexins. A single LNS domain functions as
RT   an independently folding ligand-binding unit.";
RL   J. Biol. Chem. 273:34716-34723(1998).
RN   [4]
RP   INTERACTION WITH CASK.
RX   PubMed=8786425; DOI=10.1523/jneurosci.16-08-02488.1996;
RA   Hata Y., Butz S., Suedhof T.C.;
RT   "CASK: a novel dlg/PSD95 homolog with an N-terminal calmodulin-dependent
RT   protein kinase domain identified by interaction with neurexins.";
RL   J. Neurosci. 16:2488-2494(1996).
RN   [5]
RP   INTERACTION WITH ALPHA-LATROTOXIN.
RX   PubMed=10197529; DOI=10.1016/s0896-6273(00)80704-7;
RA   Sugita S., Khvochtev M., Suedhof T.C.;
RT   "Neurexins are functional alpha-latrotoxin receptors.";
RL   Neuron 22:489-496(1999).
RN   [6]
RP   INTERACTION WITH DAG1.
RX   PubMed=11470830; DOI=10.1083/jcb.200105003;
RA   Sugita S., Saito F., Tang J., Satz J., Campbell K., Suedhof T.C.;
RT   "A stoichiometric complex of neurexins and dystroglycan in brain.";
RL   J. Cell Biol. 154:435-445(2001).
RN   [7]
RP   INTERACTION WITH CASK; CASKIN1 AND APBA1.
RX   PubMed=12040031; DOI=10.1523/jneurosci.22-11-04264.2002;
RA   Tabuchi K., Biederer T., Butz S., Suedhof T.C.;
RT   "CASK participates in alternative tripartite complexes in which Mint 1
RT   competes for binding with Caskin 1, a novel CASK-binding protein.";
RL   J. Neurosci. 22:4264-4273(2002).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH LRRTM1; LRRTM2; LRRTM3
RP   AND LRRTM4.
RX   PubMed=20064387; DOI=10.1016/j.neuron.2009.12.012;
RA   Ko J., Fuccillo M.V., Malenka R.C., Sudhof T.C.;
RT   "LRRTM2 functions as a neurexin ligand in promoting excitatory synapse
RT   formation.";
RL   Neuron 64:791-798(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH LRRTM2, SUBCELLULAR LOCATION, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=20064388; DOI=10.1016/j.neuron.2009.12.019;
RA   de Wit J., Sylwestrak E., O'Sullivan M.L., Otto S., Tiglio K., Savas J.N.,
RA   Yates J.R. III, Comoletti D., Taylor P., Ghosh A.;
RT   "LRRTM2 interacts with Neurexin1 and regulates excitatory synapse
RT   formation.";
RL   Neuron 64:799-806(2009).
RN   [10]
RP   INTERACTION WITH CASK.
RX   PubMed=25385611; DOI=10.1073/pnas.1416515111;
RA   Li Y., Wei Z., Yan Y., Wan Q., Du Q., Zhang M.;
RT   "Structure of Crumbs tail in complex with the PALS1 PDZ-SH3-GK tandem
RT   reveals a highly specific assembly mechanism for the apical Crumbs
RT   complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:17444-17449(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 1146-1361 IN COMPLEX WITH NLGN4.
RX   PubMed=18093522; DOI=10.1016/j.neuron.2007.12.002;
RA   Arac D., Boucard A.A., Ozkan E., Strop P., Newell E., Sudhof T.C.,
RA   Brunger A.T.;
RT   "Structures of neuroligin-1 and the neuroligin-1/neurexin-1 beta complex
RT   reveal specific protein-protein and protein-Ca2+ interactions.";
RL   Neuron 56:992-1003(2007).
CC   -!- FUNCTION: Cell surface protein involved in cell-cell-interactions,
CC       exocytosis of secretory granules and regulation of signal transmission
CC       (By similarity). Function is isoform-specific (By similarity). Alpha-
CC       type isoforms have a long N-terminus with six laminin G-like domains
CC       and play an important role in synaptic signal transmission (By
CC       similarity). Alpha-type isoforms play a role in the regulation of
CC       calcium channel activity and Ca(2+)-triggered neurotransmitter release
CC       at synapses and at neuromuscular junctions (By similarity). They play
CC       an important role in Ca(2+)-triggered exocytosis of secretory granules
CC       in pituitary gland (By similarity). They may affect their functions at
CC       synapses and in endocrine cells via their interactions with proteins
CC       from the exocytotic machinery (By similarity). Likewise, alpha-type
CC       isoforms play a role in regulating the activity of postsynaptic NMDA
CC       receptors, a subtype of glutamate-gated ion channels (By similarity).
CC       Both alpha-type and beta-type isoforms may play a role in the formation
CC       or maintenance of synaptic junctions via their interactions (via the
CC       extracellular domains) with neuroligin family members, CBLN1 or CBLN2
CC       (By similarity). In vitro, triggers the de novo formation of
CC       presynaptic structures (PubMed:20064387, PubMed:20064388). May be
CC       involved in specification of excitatory synapses (PubMed:20064387,
CC       PubMed:20064388). Alpha-type isoforms were first identified as
CC       receptors for alpha-latrotoxin from spider venom (PubMed:20064387,
CC       PubMed:20064388). {ECO:0000250|UniProtKB:Q9CS84,
CC       ECO:0000269|PubMed:20064387, ECO:0000269|PubMed:20064388}.
CC   -!- SUBUNIT: Interacts (via laminin G-like domain 2 and/or laminin G-like
CC       domain 6) with NLGN1 forming a heterotetramer, where one NLGN1 dimer
CC       interacts with one NRXN1 dimer (By similarity). Also interacts (via
CC       laminin G-like domain 2 and/or laminin G-like domain 6) with NLGN2,
CC       NLGN3 and NLGN4L; interactions with NLGN1, NLGN2, NLGN3 and NLGN4L are
CC       calcium-dependent (PubMed:18093522). Interacts (via cytoplasmic C-
CC       terminal region) with CASK (via the PDZ, SH3 and guanylate kinase-like
CC       domains) (PubMed:12040031, PubMed:8786425). Interacts (via cytoplasmic
CC       C-terminus) with CASKIN1 and APBA1 (PubMed:12040031). Interacts (via
CC       laminin G-like domain 2) with NXPH1 and NXPH3 (PubMed:9856994). Alpha-
CC       type isoforms (neurexin-1-alpha) interact (via laminin G-like domain 2
CC       and/or laminin G-like domain 6) with DAG1 (via alpha-dystroglycan
CC       chain) (PubMed:11470830). Interacts with LRRTM1, LRRTM2, LRRTM3 and
CC       LRRTM4 (PubMed:20064387, PubMed:20064388). Interacts with SYT13 and
CC       SYTL1 (By similarity). Interacts with CBLN1, CBLN2 and, less avidly,
CC       with CBLN4 (By similarity). Interacts with CLSTN3 (By similarity).
CC       Alpha-type isoforms interact with alpha-latrotoxin from spider venom
CC       (PubMed:10197529, PubMed:1621094). {ECO:0000250|UniProtKB:Q9CS84,
CC       ECO:0000269|PubMed:10197529, ECO:0000269|PubMed:11470830,
CC       ECO:0000269|PubMed:12040031, ECO:0000269|PubMed:1621094,
CC       ECO:0000269|PubMed:18093522, ECO:0000269|PubMed:20064387,
CC       ECO:0000269|PubMed:20064388, ECO:0000269|PubMed:8786425,
CC       ECO:0000269|PubMed:9856994}.
CC   -!- SUBCELLULAR LOCATION: Presynaptic cell membrane
CC       {ECO:0000250|UniProtKB:Q9CS84}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=17;
CC         Comment=Two isoform types, alpha-type and beta-type are produced by
CC         alternative promoter usage. In addition there are at least five
CC         alternatively spliced sites, each of which may be spliced in up to
CC         seven different ways. Combinatorial splicing at each of these five
CC         sites may lead to the generation of at least 96 isoforms but for
CC         simplicity only individual splice events or observed combinations are
CC         explicitly described below. Beta-type isoforms share the possibility
CC         of alternative splicing at sites 4 and 5. Experimental confirmation
CC         may be lacking for some isoforms. {ECO:0000269|PubMed:1621094,
CC         ECO:0000269|PubMed:7695896};
CC       Name=1a; Synonyms=Alpha-1A2A3A4A5A;
CC         IsoId=Q63372-2; Sequence=Displayed;
CC       Name=2a; Synonyms=Alpha-1B;
CC         IsoId=Q63372-1; Sequence=VSP_022560;
CC       Name=3a; Synonyms=Alpha-1C;
CC         IsoId=Q63372-3; Sequence=VSP_003486;
CC       Name=4a; Synonyms=Alpha-1D;
CC         IsoId=Q63372-4; Sequence=VSP_003488;
CC       Name=5a; Synonyms=Alpha-1E;
CC         IsoId=Q63372-5; Sequence=VSP_003486, VSP_003488;
CC       Name=6a; Synonyms=Alpha-1F;
CC         IsoId=Q63372-6; Sequence=VSP_022559;
CC       Name=7a; Synonyms=Alpha-1G;
CC         IsoId=Q63372-7; Sequence=VSP_003487;
CC       Name=8a; Synonyms=Alpha-2B;
CC         IsoId=Q63372-8; Sequence=VSP_003490;
CC       Name=9a; Synonyms=Alpha-2C;
CC         IsoId=Q63372-9; Sequence=VSP_003489;
CC       Name=10a; Synonyms=Alpha-3B;
CC         IsoId=Q63372-10; Sequence=VSP_003491;
CC       Name=11a; Synonyms=Alpha-4B;
CC         IsoId=Q63372-11; Sequence=VSP_003492;
CC       Name=12a; Synonyms=Alpha-5B;
CC         IsoId=Q63372-12; Sequence=VSP_003493;
CC       Name=13a; Synonyms=Alpha-1B2B;
CC         IsoId=Q63372-13; Sequence=VSP_022560, VSP_003490;
CC       Name=1b; Synonyms=Beta-4A5A;
CC         IsoId=Q63373-1; Sequence=External;
CC       Name=2b; Synonyms=Beta-4A5B;
CC         IsoId=Q63373-2; Sequence=External;
CC       Name=3b; Synonyms=Beta-4B5A;
CC         IsoId=Q63373-3; Sequence=External;
CC       Name=4b; Synonyms=Beta-4B5B;
CC         IsoId=Q63373-4; Sequence=External;
CC   -!- TISSUE SPECIFICITY: Brain (neuronal synapse).
CC       {ECO:0000269|PubMed:1621094, ECO:0000269|PubMed:7695896}.
CC   -!- PTM: O-glycosylated; contains heparan sulfate. Heparan sulfate
CC       attachment is required for synapse development by mediating
CC       interactions with neuroligins and LRRTM2.
CC       {ECO:0000250|UniProtKB:Q9CS84}.
CC   -!- MISCELLANEOUS: Alpha-latrotoxin competes with alpha-dystroglycan for
CC       binding.
CC   -!- SIMILARITY: Belongs to the neurexin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M96374; AAA41704.1; -; mRNA.
DR   PIR; A40228; A40228.
DR   RefSeq; NP_068535.2; NM_021767.2.
DR   PDB; 3BIW; X-ray; 3.50 A; E/F/G/H=1146-1361.
DR   PDBsum; 3BIW; -.
DR   AlphaFoldDB; Q63372; -.
DR   SMR; Q63372; -.
DR   BioGRID; 248813; 6.
DR   MINT; Q63372; -.
DR   STRING; 10116.ENSRNOP00000066979; -.
DR   GlyCosmos; Q63372; 4 sites, No reported glycans.
DR   GlyGen; Q63372; 5 sites.
DR   iPTMnet; Q63372; -.
DR   PhosphoSitePlus; Q63372; -.
DR   GeneID; 60391; -.
DR   KEGG; rno:60391; -.
DR   AGR; RGD:628659; -.
DR   CTD; 9378; -.
DR   RGD; 628659; Nrxn1.
DR   InParanoid; Q63372; -.
DR   OrthoDB; 2999458at2759; -.
DR   Reactome; R-RNO-6794361; Neurexins and neuroligins.
DR   EvolutionaryTrace; Q63372; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0044295; C:axonal growth cone; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; ISS:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0098982; C:GABA-ergic synapse; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; ISS:BHF-UCL.
DR   GO; GO:0031965; C:nuclear membrane; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0048787; C:presynaptic active zone membrane; ISO:RGD.
DR   GO; GO:0042734; C:presynaptic membrane; ISS:BHF-UCL.
DR   GO; GO:0098635; C:protein complex involved in cell-cell adhesion; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; ISO:RGD.
DR   GO; GO:0036057; C:slit diaphragm; IDA:RGD.
DR   GO; GO:0031982; C:vesicle; ISS:BHF-UCL.
DR   GO; GO:0033130; F:acetylcholine receptor binding; ISS:BHF-UCL.
DR   GO; GO:0005246; F:calcium channel regulator activity; ISS:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IDA:RGD.
DR   GO; GO:0048306; F:calcium-dependent protein binding; ISO:RGD.
DR   GO; GO:0050839; F:cell adhesion molecule binding; ISS:BHF-UCL.
DR   GO; GO:0097109; F:neuroligin family protein binding; ISS:BHF-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; ISO:RGD.
DR   GO; GO:0005105; F:type 1 fibroblast growth factor receptor binding; ISO:RGD.
DR   GO; GO:0030534; P:adult behavior; ISS:BHF-UCL.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; ISO:RGD.
DR   GO; GO:0021707; P:cerebellar granule cell differentiation; ISO:RGD.
DR   GO; GO:0007268; P:chemical synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0007623; P:circadian rhythm; IEP:RGD.
DR   GO; GO:0045184; P:establishment of protein localization; ISO:RGD.
DR   GO; GO:0046847; P:filopodium assembly; ISO:RGD.
DR   GO; GO:0097112; P:gamma-aminobutyric acid receptor clustering; ISO:RGD.
DR   GO; GO:0097116; P:gephyrin clustering involved in postsynaptic density assembly; ISS:BHF-UCL.
DR   GO; GO:0097117; P:guanylate kinase-associated protein clustering; ISO:RGD.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; ISO:RGD.
DR   GO; GO:0007612; P:learning; ISS:BHF-UCL.
DR   GO; GO:0051490; P:negative regulation of filopodium assembly; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0097118; P:neuroligin clustering involved in postsynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; ISS:BHF-UCL.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; ISO:RGD.
DR   GO; GO:0042551; P:neuron maturation; ISO:RGD.
DR   GO; GO:0031175; P:neuron projection development; ISO:RGD.
DR   GO; GO:0007269; P:neurotransmitter secretion; ISS:BHF-UCL.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; ISO:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:RGD.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; ISO:RGD.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; ISO:RGD.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0090129; P:positive regulation of synapse maturation; ISS:BHF-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISS:BHF-UCL.
DR   GO; GO:0097119; P:postsynaptic density protein 95 clustering; ISS:BHF-UCL.
DR   GO; GO:0097104; P:postsynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL.
DR   GO; GO:0099054; P:presynapse assembly; IDA:SynGO.
DR   GO; GO:0097105; P:presynaptic membrane assembly; ISO:RGD.
DR   GO; GO:0035418; P:protein localization to synapse; ISO:RGD.
DR   GO; GO:0090126; P:protein-containing complex assembly involved in synapse maturation; ISO:RGD.
DR   GO; GO:0097120; P:receptor localization to synapse; ISO:RGD.
DR   GO; GO:2000821; P:regulation of grooming behavior; ISS:BHF-UCL.
DR   GO; GO:0099151; P:regulation of postsynaptic density assembly; ISO:RGD.
DR   GO; GO:0099150; P:regulation of postsynaptic specialization assembly; ISO:RGD.
DR   GO; GO:1905606; P:regulation of presynapse assembly; ISO:RGD.
DR   GO; GO:0098693; P:regulation of synaptic vesicle cycle; ISO:RGD.
DR   GO; GO:0150036; P:regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission; ISO:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   GO; GO:0035176; P:social behavior; ISO:RGD.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0099560; P:synaptic membrane adhesion; ISO:RGD.
DR   GO; GO:0097091; P:synaptic vesicle clustering; ISO:RGD.
DR   GO; GO:0099550; P:trans-synaptic signaling, modulating synaptic transmission; ISO:RGD.
DR   GO; GO:0006904; P:vesicle docking involved in exocytosis; IMP:MGI.
DR   GO; GO:0042297; P:vocal learning; ISO:RGD.
DR   GO; GO:0071625; P:vocalization behavior; ISO:RGD.
DR   CDD; cd00054; EGF_CA; 1.
DR   CDD; cd00110; LamG; 6.
DR   Gene3D; 2.60.120.200; -; 6.
DR   Gene3D; 2.10.25.10; Laminin; 3.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR003585; Neurexin-like.
DR   InterPro; IPR050372; Neurexin-related_CASP.
DR   PANTHER; PTHR15036:SF51; NEUREXIN-1; 1.
DR   PANTHER; PTHR15036; PIKACHURIN-LIKE PROTEIN; 1.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF02210; Laminin_G_2; 6.
DR   SMART; SM00294; 4.1m; 1.
DR   SMART; SM00181; EGF; 3.
DR   SMART; SM00282; LamG; 6.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 6.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS50026; EGF_3; 3.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing; Calcium;
KW   Cell adhesion; Cell membrane; Cell projection; Direct protein sequencing;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Heparan sulfate; Membrane;
KW   Metal-binding; Proteoglycan; Reference proteome; Repeat; Signal; Synapse;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000269|PubMed:9856994"
FT   CHAIN           31..1530
FT                   /note="Neurexin-1"
FT                   /id="PRO_0000019491"
FT   TOPO_DOM        31..1454
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1455..1475
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1476..1530
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          31..217
FT                   /note="Laminin G-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          213..255
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          299..496
FT                   /note="Laminin G-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          503..695
FT                   /note="Laminin G-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          699..736
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          741..914
FT                   /note="Laminin G-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          928..1103
FT                   /note="Laminin G-like 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          1106..1143
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1149..1347
FT                   /note="Laminin G-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   REGION          196..219
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1412..1443
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1497..1530
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1497..1523
FT                   /note="Interaction with CASK"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CS84"
FT   COMPBIAS        1497..1513
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1514..1530
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         345
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   BINDING         362
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   BINDING         430
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   BINDING         788
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   BINDING         805
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   BINDING         864
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   BINDING         1199
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CS84"
FT   BINDING         1216
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CS84"
FT   BINDING         1298
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CS84"
FT   BINDING         1300
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CS84"
FT   CARBOHYD        125
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        190
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        813
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1246
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1408
FT                   /note="O-linked (Xyl...) (heparan sulfate) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CS84"
FT   DISULFID        228..243
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        245..255
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        460..496
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        666..695
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        703..714
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        708..723
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        725..735
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        906..914
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        1075..1103
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        1110..1121
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        1115..1130
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   DISULFID        1132..1142
FT                   /evidence="ECO:0000250|UniProtKB:Q28146"
FT   VAR_SEQ         258..277
FT                   /note="Missing (in isoform 7a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003487"
FT   VAR_SEQ         258
FT                   /note="Missing (in isoform 3a and isoform 5a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003486"
FT   VAR_SEQ         264..273
FT                   /note="Missing (in isoform 6a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_022559"
FT   VAR_SEQ         274..277
FT                   /note="Missing (in isoform 4a and isoform 5a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003488"
FT   VAR_SEQ         278..293
FT                   /note="Missing (in isoform 2a and isoform 13a)"
FT                   /evidence="ECO:0000303|PubMed:1621094"
FT                   /id="VSP_022560"
FT   VAR_SEQ         395..409
FT                   /note="Missing (in isoform 9a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003489"
FT   VAR_SEQ         403..409
FT                   /note="Missing (in isoform 8a and isoform 13a)"
FT                   /evidence="ECO:0000303|PubMed:1621094"
FT                   /id="VSP_003490"
FT   VAR_SEQ         806..815
FT                   /note="DCIRINCNSS -> G (in isoform 10a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003491"
FT   VAR_SEQ         1263..1292
FT                   /note="Missing (in isoform 11a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003492"
FT   VAR_SEQ         1426..1427
FT                   /note="Missing (in isoform 12a)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_003493"
FT   STRAND          1146..1161
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   HELIX           1164..1166
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1170..1180
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1184..1194
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1200..1206
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1209..1219
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1221..1224
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1232..1234
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1236..1243
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1246..1251
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1257..1259
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1301..1309
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   TURN            1310..1313
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1318..1325
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   HELIX           1330..1335
FT                   /evidence="ECO:0007829|PDB:3BIW"
FT   STRAND          1341..1350
FT                   /evidence="ECO:0007829|PDB:3BIW"
SQ   SEQUENCE   1530 AA;  167923 MW;  548109BAF05119FC CRC64;
     MGTALVQHGG CCLLCLSLLL LGCWAELGSG LEFPGAEGQW TRFPKWNACC ESEMSFQLKT
     RSARGLVLYF DDEGFCDFLE LILTRGGRLQ LSFSIFCAEP ATLLADTPVN DGAWHSVRIR
     RQFRNTTLYI DRAEAKWVEV KSKRRDMTVF SGLFVGGLPP ELRAAALKLT LASVREREPF
     KGWIRDVRVN SSQALPVDGS EVKLDEEPPN SGGGSPCEAG DEGDGGVCLN GGVCSVVDDQ
     AVCDCSRTGF RGKDCSQEDN NVEGLAHLMM GDQGKSKEDN NVEGLAHLMM GDQGKEEYIA
     TFKGSEYFCY DLSQNPIQSS SDEITLSFKT LQRNGLMLHT GKSADYVNLA LKNGAVSLVI
     NLGSGAFEAL VEPVNGKFND NAWHDVKVTR NLRQHSGIGH AMVNKLHCSV TISVDGILTT
     TGYTQEDYTM LGSDDFFYVG GSPSTADLPG SPVSNNFMGC LKEVVYKNND VRLELSRLAK
     QGDPKMKIHG VVAFKCENVA TLDPITFETP ESFISLPKWN AKKTGSISFD FRTTEPNGLI
     LFSHGKPRHQ KDAKHPQMIK VDFFAIEMLD GHLYLLLDMG SGTIKIKALQ KKVNDGEWYH
     VDFQRDGRSG TISVNTLRTP YTAPGESEIL DLDDELYLGG LPENKAGLVF PTEVWTALLN
     YGYVGCIRDL FIDGQSKDIR QMAEIQSTAG VKPSCSRETA KPCLSNPCKN NGMCRDGWNR
     YVCDCSGTGY LGRSCEREAT VLSYDGSMFM KIQLPVVMHT EAEDVSLRFR SQRAYGILMA
     TTSRDSADTL RLELDAGRVK LTVNLDCIRI NCNSSKGPET LFAGYNLNDN EWHTVRVVRR
     GKSLKLTVDD QQAMTGQMAG DHTRLEFHNI ETGIITERRY LSSVPSNFIG HLQSLTFNGM
     AYIDLCKNGD IDYCELNARF GFRNIIADPV TFKTKSSYVA LATLQAYTSM HLFFQFKTTS
     LDGLILYNSG DGNDFIVVEL VKGYLHYVFD LGNGANLIKG SSNKPLNDNQ WHNVMISRDT
     SNLHTVKIDT KITTQITAGA RNLDLKSDLY IGGVAKETYK SLPKLVHAKE GFQGCLASVD
     LNGRLPDLIS DALFCNGQIE RGCEGPSTTC QEDSCSNQGV CLQQWDGFSC DCSMTSFSGP
     LCNDPGTTYI FSKGGGQITH KWPPNDRPST RADRLAIGFS TVQKEAVLVR VDSSSGLGDY
     LELHIHQGKI GVKFNVGTDD IAIEESNAII NDGKYHVVRF TRSGGNATLQ VDSWPVIERY
     PAGNNDNERL AIARQRIPYR LGRVVDEWLL DKGRQLTIFN SQATIIIGGK EQGQPFQGQL
     SGLYYNGLKV LNMAAENDAN IAIVGNVRLV GEVPSSMTTE STATAMQSEM STSIMETTTT
     LATSTARRGK PPTKEPISQT TDDILVASAE CPSDDEDIDP CEPSSGGLAN PTRVGGREPY
     PGSAEVIRES SSTTGMVVGI VAAAALCILI LLYAMYKYRN RDEGSYHVDE SRNYISNSAQ
     SNGAVVKEKQ PSSAKSANKN KKNKDKEYYV
//
